drugset
drugset / Trial / NCT03573310

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

NCT03573310 ↗

Phase 1 Completed 114 enrolled Janssen Research & Development, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced solid tumors and also to identify the recommended Phase 2 dose(s) (RP2Ds) of JNJ-64619178 for NHL and advanced solid tumors (Part 1) and to confirm the tolerability of JNJ-64619178 in participants with lower risk myelodysplastic syndromes (MDS) (Part 2).

Timeline

Start
2018-07-13
Primary completion
2025-09-25
Completion
2025-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject ONAMETOSTAT Small molecule — Oral

Indications

cancer myelodysplastic syndrome non-Hodgkin lymphoma